Research programme: gene editing therapeutics - Mammoth Biosciences/Regeneron Pharmaceuticals
Latest Information Update: 24 May 2024
At a glance
- Originator Mammoth Biosciences; Regeneron Pharmaceuticals
- Class Gene therapies
- Mechanism of Action Gene expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Unspecified